Chengye Medical's Key Subsidiary Fukan Vitality Pharmaceutical Announces Board Resolution on Cash Capital Increase and New Share Issuance

1. Board resolution date: 115/06/26 2. Source of capital increase: Issuance of new shares via cash capital increase 3. Whether the issuance of new shares is under a comprehensive filing (if yes, specify the planned issuance period; if no): No 4. Total issuance amount and number of shares (for capital increases from retained earnings or reserves, exclude shares allocated to employees): Total issuance amount of NT$77,466,400, 880,300 ordinary shares 5. Issuance amount and number of shares for this round under a comprehensive filing: Not applicable 6. Remaining amount and number of shares after this issuance under a comprehensive filing: Not applicable 7. Par value per share: NT$10 8. Issue price: NT$88 9. Number of shares for employee subscription or allocation amount: 88,030 shares 10. Number of publicly offered shares: Not applicable 11. Subscription or free allocation ratio for existing shareholders: 90% 12. Handling of fractional shares and unclaimed shares after the subscription deadline: Authorized for the Chairman to arrange subscriptions with specific individuals 13. Rights and obligations of the newly issued shares: Same rights and obligations as existing shares 14. Use of capital increase funds: To strengthen operational funding 15. Rationality and necessity of fundraising after a cash reduction in capital (applicable if cash reduction was conducted in the current or previous year): Not applicable 16. Other matters to be disclosed: None